FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Schilke Tobin 2. Issuer Name and Ticker or Trading Symbol Revance Therapeutics, Inc. [ RVNC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CFO
(Last)         (First)         (Middle)
C/O REVANCE THERAPEUTICS, INC., 1222 DEMONBREUN STREET, SUITE 2000
3. Date of Earliest Transaction (MM/DD/YYYY)
6/30/2021
(Street)
NASHVILLE, TN 37203
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/30/2021    J(1)   V 446  A $24.089  69208  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Schilke Tobin
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, SUITE 2000
NASHVILLE, TN 37203


CFO

Signatures
/s/ Gordon Ho, Attorney-in-Fact 7/2/2021
**Signature of Reporting Person Date
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Revance Therapeutics Charts.
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Revance Therapeutics Charts.